<DOC>
	<DOCNO>NCT01006616</DOCNO>
	<brief_summary>Neutrophils think play important role pathophysiology chronic obstructive pulmonary disease ( COPD ) . Navarixin ( SCH 527123 , MK-7123 ) antagonist cysteine-X-cysteine chemokine receptor 2 ( CXCR2 ) think reduce neutrophil migration diseased lung . It theorize reduce neutrophil migration diseased lung improve participant 's symptoms natural history disease . The study consist 2-week screening period follow 2-year ( 104-week ) double-blind treatment period . The 2-year Treatment Period make two phase : 26-week ( 6-month ) dose range-finding phase 3 active arm 1 placebo arm ( Period 1 ) , follow 78-week ( 18-month ) long-term safety efficacy phase ( Period 2 ) . Participants participate original 6-month study ( Period 1 ) may elect continue 18-month extension study ( Period 2 ) . Hypothesis : navarixin , 50 mg , high remain dose 50-mg dose discontinue , superior placebo respect improve airflow .</brief_summary>
	<brief_title>Long-Term Study Effects Navarixin ( SCH 527123 , MK-7123 ) Participants With Moderate Severe COPD ( MK-7123-019 )</brief_title>
	<detailed_description />
	<criteria>Diagnosis COPD least 2 year base American Thoracic Society/European Respiratory Society ( ATS/ERS ) current guideline symptom consistent COPD least 2 year . &gt; 40 &lt; =75 year age , either sex , race . No exacerbation respiratory infection past 6 week . Smoker exsmoker 10 packyear history . Diagnosis asthma clinically relevant lung disease ( COPD ) , i.e. , sarcoidosis , tuberculosis , pulmonary fibrosis , severe bronchiectasis , lung cancer . Significant Xray finding . Use supplemental oxygen &gt; 12 hours/day .</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>